PERSONALIZ3D™ Peptides

3D-printed peptides and longevity products, dosed for one patient, with no heat and no UV.

A U.S. pathway for compounded peptides just opened.

An HHS policy issued in October 2026 lets 503A pharmacies compound six peptides. Only two, KPV and BPC-157, are covered for oral use, and those are the peptides we print. Because the CraftMake™ printer works at room temperature with no heat and no UV, fragile peptides stay intact.

HHS policy notice, Docket HHS-OASH-2026-0496 (Oct. 2026). The policy is interim enforcement discretion, not FDA approval, and may be revised or applied differently by states. Market figure in USD: Grand View Research, Peptide Therapeutics; not independently verified by the Company.

6Peptides 503A pharmacies may compound under the HHS policy (Oct. 2026)

2Covered for oral use: KPV and BPC-157

BPC-157 and KPV as a gummy, tablet or pellet.

BPC-157 · KPV

Gummy

Layered, single-dose or core-and-shell gummies, printed at 25°C with no UV, so fragile peptides stay intact.

BPC-157 · KPV

Tablet

Printed at any strength from one recipe, so each tablet matches the dose on the prescription.

BPC-157 · KPV

Pellet

Small printed pellets dosed to the prescription, from the same validated recipe.

About these formatsFormats shown are concepts. 503A products are patient-specific compounded prescriptions and are not FDA-approved. BPC-157 and KPV may be compounded only as the HHS policy allows. No efficacy claims are made.

Longevity gummy

NAD+ and NMN in one gummy, two layers.

A combination no fixed-ratio product can match: each gummy is printed at the ratio and strength a clinician prescribes.

Formats shown are concepts. 503A products are patient-specific compounded prescriptions and are not FDA-approved; no efficacy claims are made. Source: Grand View Research, NAD+ Products (2025); figures in USD, not independently verified by the Company.

2 layersNAD+ and NMN printed together in one gummy

Per patientRatio and strength set by the prescribing clinician

$3.9B → $12.2BNAD+ products market, 2025 → 2033

25°CPrinted with no heat and no UV

A pill-in-pill that opens in the colon.

KPV and BPC-157 in the patent-pending CORR3CT™ design. A printed shell holds the peptide through the stomach and small intestine, then releases it in the colon, where the disease is. Printed with no heat, so fragile peptides stay intact.

1 · Stomach

Shell holds in acid

The outer shell protects the peptide core from stomach acid.

2 · Small intestine

Shell keeps holding

The shell stays closed as the pill moves through the small intestine.

3 · Colon

Peptide released where the disease is

The core opens in the colon, the part of the gut most oral products are not designed to reach.

12,000×Lower KPV dose gave a similar effect when delivered to the colon (mouse colitis study)

Up to 75%Of the dose reached a simulated colon, vs. under 10% for a commercial product (in vitro)

30–60%Of ulcerative colitis patients have disease in the lower colon

600–900KAmericans with ulcerative colitis

$29.6BGlobal IBD treatment market, 2025

2027Planned launch with telehealth and pharmacy partners

Animal (mouse colitis) and in vitro (budesonide model) data; results in humans are not established. Compounded peptides are not FDA-approved; the HHS policy is interim and may be revised or applied differently by states. No efficacy claims are made. Sources: PharmaTher news release, Oct. 29, 2026; HHS policy notice (Docket HHS-OASH-2026-0496); Grand View Research; NIDDK. Market data in USD, not independently verified by the Company. Launch timing is a forward-looking internal estimate.

Made at a 503A compounding pharmacy.

Through clinicians and telehealth

Each prescription is printed a U.S. 503A compounding pharmacy and sold through clinicians and telehealth: an online visit, a printed prescription, shipped home.

See telehealth programs

For telehealth platforms and pharmacies

Add our printed peptides under your own brand, powered by M3DICINES™, without building a lab. Pharmacy partners can also bring CraftMake™ printing in-house.

Partner with us

Compounded (503A) products are patient-specific prescriptions prepared by licensed pharmacies and are not FDA-approved. The HHS policy (Oct. 2026, Docket HHS-OASH-2026-0496) lets 503A pharmacies compound six peptides, with only KPV and BPC-157 for oral use; it is interim enforcement discretion, not FDA approval, and may be revised or applied differently by states. Oral formulations require PharmaTher validation and stability work. No efficacy claims are made. Launch timing and milestones are internal estimates and forward-looking; see forward-looking statements.